{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-23-003436","form_type":"8-K","ticker":"CRSP","cik":"0001674416","company_name":"CRISPR Therapeutics AG","filed_at":"2023-02-21T23:59:59+00:00","discovered_at":"2026-05-14T18:03:46.094016+00:00","generated_at":"2026-06-19T07:05:00.825653+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"CRISPR Therapeutics reports FY2022 net loss of $650.2M; exa-cel regulatory submissions complete in Europe","bullets":["Cash, cash equivalents and marketable securities were $1,868.4M as of Dec 31, 2022, down from $2,379.1M a year ago.","R&D expenses for FY2022 were $461.6M, up from $340.6M in FY2021, driven by pipeline advancement.","Net loss for FY2022 was $650.2M, compared to net income of $377.7M in FY2021, due to lower collaboration revenue.","Regulatory submissions for exa-cel (CTX001) completed in Europe; U.S. BLA rolling submission on track for Q1 2023.","Enrolling and dosing ongoing for CTX110 (CD19+ B-cell malignancies) and CTX130 (CD70+ T cell lymphomas); next-gen CAR T trials initiating."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-23-003436","json":"https://secwatch.observer/filing/0000950170-23-003436.json","markdown":"https://secwatch.observer/filing/0000950170-23-003436.md","text":"https://secwatch.observer/filing/0000950170-23-003436.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/0000950170-23-003436-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/crsp-20230221.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-19T07:05:00.825653+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"2837ff7ef64fa5717896a88191e454ca8b168581","claim":"CRISPR Therapeutics AG reported financial results for the fourth quarter and full year ended December 31, 2022.","evidence_excerpt":"On February 21, 2023, CRISPR Therapeutics AG announced its financial results for the quarter and year ended December 31, 2022 and other business highlights.","evidence_source":"SEC 8-K Item 2.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1674416/000095017023003436/0000950170-23-003436-index.htm","confidence":0.9,"family_label":"Earnings Releases","details":[{"label":"Period","value":"the fourth quarter and full year ended December 31, 2022"},{"label":"Result","value":"reported results"}],"fact_type":"earnings_release"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}